The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review. 
Ovarian cancer is the leading cause of death from gynecologic cancers, in fact, >80% of cases are diagnosed as advanced-stage disease associated with a high mortality rate (<40% of women cured).  A systematic review was performed to estimate the role of HE4 in the diagnosis, prognosis and follow-up of ovarian tumors.  Areas covered: A comprehensive search of the literature from January 1952 to August 2016 was conducted using the terms 'ovarian tumor' and 'ovarian cancer' combined with 'HE4' and 'human epididymis protein 4'.  The search identified a total of 259 citations, of which 141 were potentially relevant after initial evaluation.  Of these studies, 75 primary studies met the inclusion criteria and were analyzed, with a total of 14,773 patients.  Expert commentary: Serum HE4 dosage is a useful preoperative test for predicting the benign or malignant nature of pelvic masses.  It seems to have a promising role in the prediction of clinical and surgical outcomes.  Moreover, HE4 seems to better predict recurrence in comparison to CA-125.